Atea Pharmaceuticals, Inc.
No SEC Form 4 filings for $AVIR in the last 30 days.
See all $AVIR insider activity →Atea Pharmaceuticals (AVIR) reported Q2 2026 earnings, highlighting $219.5M in cash and marketable securities, a net loss of $32.9M, and a 93.9% SVR rate for its lead regimen BEM/RZR. Management projected a cash runway through 2027 and a commercial launch in mid-2028. The company also initiated Phase 1 trials for AT-587, targeting chronic hepatitis E.
Atea Pharmaceuticals, Inc. (AVIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d165663dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Support
Atea Pharmaceuticals (Nasdaq: AVIR) said it started a first-in-human Phase 1 trial of AT-587, an oral nucleotide analog for hepatitis E virus (HEV), in healthy volunteers. The randomized, double-blind, placebo-controlled study will assess safety, tolerability and PK, with single and multiple ascending doses plus a food-effect arm. Preclinical data cited include 30-150x in vitro potency vs sofosbuvir/ribavirin and in vivo genotype 3 activity.
Over the past 7 days, alphai's AI scored 1 news story mentioning AVIR (Atea Pharmaceuticals, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent AVIR coverage spans financial news, earnings and technology.
The disclosed loss and cash position suggest near‑term financing pressure, while positive Phase 3 data and a 2027 NDA target could drive upside if milestones are met.
Positive Phase 3 readout plus updated clinical timelines and cash/R&D changes create a near-term catalyst path toward potential 2027 NDA.
Phase 1 initiation is a meaningful pipeline milestone that can improve perceived clinical progress, but it is early and lacks efficacy readouts.
Routine shareholder-meeting vote results; unlikely to change near-term fundamentals, but confirms governance outcomes.
The director's purchase of 6,100 shares at an average price of $4.1715 signals insider confidence, which may positively influence investor sentiment.
alphai scores every news story that mentions AVIR with an AI model for sentiment and relevance, and aggregates insider trades from Atea Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Atea Pharmaceuticals (AVIR) reported Q2 2026 earnings, highlighting $219.5M in cash and marketable securities, a net loss of $32.9M, and a 93.9% SVR rate for its lead regimen BEM/RZR. Management projected a cash runway through 2027 and a commercial launch in mid-2028. The company also initiated Phase 1 trials for AT-587, targeting chronic hepatitis E.
3 min readAtea Pharmaceuticals, Inc. (AVIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d165663dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Support
6 min readAtea Pharmaceuticals (Nasdaq: AVIR) said it started a first-in-human Phase 1 trial of AT-587, an oral nucleotide analog for hepatitis E virus (HEV), in healthy volunteers. The randomized, double-blind, placebo-controlled study will assess safety, tolerability and PK, with single and multiple ascending doses plus a food-effect arm. Preclinical data cited include 30-150x in vitro potency vs sofosbuvir/ribavirin and in vivo genotype 3 activity.
3 min readAtea Pharmaceuticals, Inc. (AVIR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001593899 0001593899 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18,
3 min readAtea Pharmaceuticals director Polly A. Murphy purchased 6,100 shares of Common Stock on the open market at a weighted average price of $4.1715 per share on May 18, 2026. This transaction increased her direct ownership to 92,145 shares. The filing, an amended Form 4/A, corrected the transaction date from May 18, 2025, to May 18, 2026.
2 min readThis article reports that the price target for Atea Pharmaceuticals (AVIR) has been increased by 25.00%, raising it to $10.20. It's concise and focuses solely on this financial adjustment.
2 min readShares of Atea Pharmaceuticals (NASDAQ:AVIR) reached a new 52-week high of $6.39 on Tuesday. This rise comes despite mixed analyst sentiment, with a consensus "Hold" rating and a target price of $6.00, and a recent EPS miss. The company, a clinical-stage antiviral developer, has seen increased institutional ownership.
3 min readImage source: The Motley Fool.Nov. 12, 2025, 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
3 min readCompany Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ET Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ET ...
2 min readAtea Pharmaceuticals ( NASDAQ:AVIR ) , a biopharmaceutical company focused on developing therapies for viral diseases, reported its second quarter 2025 results on August 7, 2025. The release highlighted improving cost controls and continued advancement in its Phase 3 clinical program for ...
3 min read
